首页> 外文期刊>Biochemical and Biophysical Research Communications >Neuronal glycosylation differentials in normal, injured and chondroitinase-treated environments
【24h】

Neuronal glycosylation differentials in normal, injured and chondroitinase-treated environments

机译:神经元糖基化在正常,损伤和软骨素治疗环境中的差异

获取原文
获取原文并翻译 | 示例
           

摘要

Glycosylation is found ubiquitously throughout the central nervous system (CNS). Chondroitin sulphate proteoglycans (CSPGs) are a group of molecules heavily substituted with glycosaminoglycans (GAGs) and are found in the extracellular matrix (ECM) and cell surfaces. Upon CNS injury, a glial scar is formed, which is inhibitory for axon regeneration. Several CSPGs are up-regulated within the glial scar, including NG2, and these CSPGs are key inhibitory molecules of axonal regeneration. Treatment with chondroitinase ABC (ChABC) can neutralise the inhibitory nature of NG2. A gene expression dataset was mined in silico to verify differentially regulated glycosylation-related genes in neurons after spinal cord injury and identify potential targets for further investigation. To establish the glycosylation differential of neurons that grow in a healthy, inhibitory and ChABC-treated environment, we established an indirect co-culture system where PC12 neurons were grown with primary astrocytes, Neu7 astrocytes (which overexpress NG2) and Neu7 astrocytes treated with ChABC. After 1, 4 and 8. days culture, lectin cytochemistry of the neurons was performed using five fluorescently-labelled lectins (ECA MAA, PNA, SNA-I and WFA). Usually α-(2,6)-linked sialylation scarcely occurs in the CNS but this motif was observed on the neurons in the injured environment only at day 8. Treatment with ChABC was successful in returning neuronal glycosylation to normal conditions at all timepoints for MAA, PNA and SNA-I staining, and by day 8 in the case of WFA. This study demonstrated neuronal cell surface glycosylation changes in an inhibitory environment and indicated a return to normal glycosylation after treatment with ChABC, which may be promising for identifying potential therapies for neuronal regeneration strategies.
机译:在整个中枢神经系统(CNS)中普遍发现糖基化。软骨素硫酸盐蛋白多糖(CSPG)是一种用糖胺聚糖(GAG)重取的一组分子,并且在细胞外基质(ECM)和细胞表面中发现。在CNS损伤时,形成胶质疤痕,这是轴突再生的抑制作用。几个CSPG在胶质瘢痕内上调,包括NG2,这些CSPG是轴突再生的关键抑制分子。用软骨素酶ABC(CHABC)治疗可以中和NG2的抑制性质。在硅损伤后在硅中挖掘基因表达数据集以验证神经元中的差异调节的糖基化相关基因,并确定进一步调查的潜在目标。为了建立在健康,抑制和脱钩治疗的环境中生长的神经元的糖基化差异,我们建立了一种间接的共培养系统,其中PC12神经元与原发性星形胶质细胞生长,Neu7星形细胞(其过度表达NG2)和Neu7星形胶质细胞用CHABC处理。在1,4和8.天培养后,使用五种荧光标记的凝集素(ECA Maa,PNA,SNA-I和WFA)进行神经元的凝集素细胞化学。通常α-(2,6) - 在CNS中几乎没有发生唾液酸,但在第8天仅在受伤环境中的神经元中观察到该基序。用CHABC的处理成功地将神经元糖基化返回到MAA的所有时间点的正常条件。 ,PNA和SNA-I染色,以及WFA的第8天。该研究表明了神经元细胞表面糖基化在抑制环境中的变化,并用CHABC处理后表明恢复正常糖基化,这可能是识别神经元再生策略的潜在疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号